DUL Stock Price, Chart, Stats & News

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies based on ribonucleic acid interference (RNAi) technology. The company's diverse pipeline of experimental RNAi therapeutics addresses a variety of serious conditions, including inherited genetic disorders, cardiometabolic ailments, hepatic infectious diseases, and diseases affecting the central nervous system (CNS) and eyes. Currently, Alnylam markets several key products: ONPATTRO (patisiran), an injection for adults suffering from polyneuropathy due to hereditary transthyretin-mediated amyloidosis; GIVLAARI, approved for the treatment of acute hepatic porphyria (AHP) in adults; and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1).